Gut microbiome-depleting antibiotic regimens are not tolerated by all mouse strains: learn from (our) bitter experience

Andrew A. Almonte, George Cavic, Teresa Neeman, Anselm Enders, Aude M. Fahrer

Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

1 Citation (Scopus)

Résumé

Why the gut microbiome is critical for the success of checkpoint inhibitor cancer therapy is a question that remains unanswered, but progress has slowed. We argue that this lack of advancement is due to an unappreciated biological detail. Here, we show that the antibiotic cocktail used in seminal publications - all of which have used the C57BL/6 mouse strain - are bitter and not tolerated by other common mouse strains (ie, BALB/c and DBA/2). We write to alert readers of this important biological limitation that must be considered when planning cancer experiments investigating the gut microbiota, to prevent the unnecessary dehydration of experimental animals, and to save our colleagues valuable experimental time and resources.

langue originaleAnglais
Numéro d'articlee005575
journalJournal for ImmunoTherapy of Cancer
Volume10
Numéro de publication11
Les DOIs
étatPublié - 2 nov. 2022
Modification externeOui

Contient cette citation